Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Breast Cancer Res Treat
; 174(2): 433-442, 2019 Apr.
Article
in En
| MEDLINE
| ID: mdl-30536182
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Doxorubicin
/
Receptor, ErbB-2
/
Cyclophosphamide
/
Metformin
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Breast Cancer Res Treat
Year:
2019
Type:
Article
Affiliation country:
Italy